Polypeptide and immune modulation
The present invention relates to Roseburia flagellin, and/or a polynucleotide sequence encoding said Roseburia flagellin, and/or a vector comprising said polynucleotide sequence, and/or a host cell, including bacteria, comprising said vector, and/or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.
1. A method of treating a gastrointestinal inflammatory disorder or an autoimmune disorder, comprising administering to a subject in need thereof a Roseburia flagellin,
wherein said Roseburia flagellin is a FlaA1 polypeptide with a sequence that has at least 95% identity to SEQ ID NO:2 or a fragment thereof, and
wherein said Roseburia flagellin comprises amino acids 79-117 of SEQ ID NO:2 and binds to TLR5.
2. The method according to claim 1 wherein the gastrointestinal inflammatory disorder or autoimmune disorder affects an alimentary canal, or a section thereof, of said subject.
3. The method according to claim 1 wherein the gastrointestinal inflammatory disorder or autoimmune disorder affects a mucosal site of said subject, such as an esophagus, stomach, or intestine.
4. The method according to claim 1 wherein the gastrointestinal inflammatory disorder or autoimmune disorder affects an intestine.
5. The method according to claim 1 wherein the subject is treated for an autoimmune disorder, wherein the autoimmune disorder is neutropenia.
6. The method according to claim 1 wherein said Roseburia flagellin comprises the polypeptide of SEQ ID NO:2 or a fragment thereof.
7. The method according to claim 1 wherein the Roseburia flagellin is a truncated FlaA1 polypeptide, and wherein said truncated FlaA1 polypeptide binds to TLR5 when administered to the subject.
8. The method according to claim 7 wherein the subject is administered the truncated FlaA1 polypeptide, wherein the truncated FlaA1 polypeptide comprises at least 40 amino acids of a polypeptide of SEQ ID NO:2.
9. The method of claim 1 , wherein the subject is treated for a gastrointestinal inflammatory disorder selected from the group consisting of irritable bowel syndrome (IBS), colitis, and inflammatory bowel disorder (IBD).
10. The method of claim 1 , wherein the subject is treated for a gastrointestinal inflammatory disorder, wherein the gastrointestinal inflammatory disorder is Crohn's disease.
11. The method of claim 1 , wherein the subject is treated for an autoimmune disorder selected from the group consisting of ulcerative colitis and pouchitis.
12. The method of claim 1 , wherein said FlaA1 polypeptide has at least 97% identity to the polypeptide of SEQ ID NO:2 or a fragment thereof.
13. The method of claim 1 , wherein said FlaA1 polypeptide has at least 98% identity to the polypeptide of SEQ ID NO:2 or a fragment thereof.
14. The method of claim 1 , wherein said FlaA1 polypeptide has at least 99% identity to the polypeptide of SEQ ID NO:2 or a fragment thereof.
15. The method of claim 7 , wherein the subject is administered the truncated FlaA1 polypeptide, and wherein the truncated FlaA1 polypeptide comprises at least 50 amino acids of a polypeptide of SEQ ID NO:2.
16. The method of claim 7 , wherein the subject is administered the truncated FlaA1 polypeptide, and wherein the truncated FlaA1 polypeptide comprises at least 75 amino acids of a polypeptide of SEQ ID NO:2.
17. The method of claim 7 , wherein the subject is administered the truncated FlaA1 polypeptide, and wherein the truncated FlaA1 polypeptide comprises at least 100 amino acids of a polypeptide of SEQ ID NO:2.
18. The method of claim 7 , wherein the subject is administered the truncated FlaA1 polypeptide, and wherein the truncated FlaA1 polypeptide comprises at least 125 amino acids of a polypeptide of SEQ ID NO:2.
19. The method of claim 7 , wherein the subject is administered the truncated FlaA1 polypeptide, and wherein the truncated FlaA1 polypeptide comprises at least 150 amino acids of a polypeptide of SEQ ID NO:2.
20. The method according to claim 7 , wherein the subject is administered the truncated FlaA1 polypeptide, and wherein the truncated FlaA1 polypeptide comprises at least 175 amino acids of a polypeptide of SEQ ID NO:2.
21. The method of claim 1 , wherein the subject is treated for a gastrointestinal inflammatory disorder.
22. The method of claim 1 , wherein the subject is treated for an autoimmune disorder.